Literature DB >> 12895266

Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine.

Pablo Muriel1, Rogelio Deheza.   

Abstract

BACKGROUND/AIMS: To evaluate liver-beneficial properties of metadoxine, not related with alcohol metabolism, bioactivation of external toxins or antioxidant mechanisms, the chronic bile duct ligation (BDL) model was used and results were compared with colchicine.
METHODS: Seven groups (n=6) of male Wistar rats were used. Four groups were BDL and received metadoxine (60 mg/kg/12 h i.p.), colchicine (10 microg/rat/day/p.o.), both or vehicles; three groups were sham-appropriate controls. Collagen content was determined by measuring hydroxyproline in liver samples; malondialdehyde (MDA) was used to estimate lipid peroxidation levels; glycogen was determined utilizing the anthrone reagent; gomory's trichromic stains of liver sections were performed.
RESULTS: Collagen increased four-fold by BDL, metadoxine, colchicine or both prevented fibrosis partially; MDA levels increased three-fold by BDL and no treatment had any significant effect; glycogen was almost depleted in the cirrhotic group, metadoxine preserved glycogen; bilirubins, and alanine aminotransferase and gamma-glutamyltranspeptidase activities increased several-fold in the BDL group, and both drugs prevented these effects partially. The histopathological analysis correlated with biochemical data.
CONCLUSIONS: Both compounds showed similar antifibrotic properties; metadoxine was more effective in preserving glycogen. Besides its antioxidant effects and its ability to induce alcohol metabolism, metadoxine possesses important antifibrotic and antinecrotic properties, and maintains energy stores efficiently.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895266     DOI: 10.1034/j.1600-0676.2003.00837.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats.

Authors:  Mukaddes Esrefoglu; Mehmet Gül; Memet-Hanifi Emre; Alaattin Polat; Mukadder-Ayse Selimoglu
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

2.  Nesfatin-1 alleviates extrahepatic cholestatic damage of liver in rats.

Authors:  Ali Solmaz; Osman Bilgin Gülçiçek; Candaş Erçetin; Hakan Yiğitbaş; Erkan Yavuz; Sinan Arıcı; Can Erzik; Oğuzhan Zengi; Pelin Demirtürk; Atilla Çelik; Fatih Çelebi
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

3.  Time course of collagen peak in bile duct-ligated rats.

Authors:  Orhan Tarcin; Metin Basaranoglu; Veysel Tahan; Gülgün Tahan; Ilker Sücüllü; Nevin Yilmaz; Gagan Sood; Ned Snyder; Gilbert Hilman; Cigdem Celikel; Nurdan Tözün
Journal:  BMC Gastroenterol       Date:  2011-04-28       Impact factor: 3.067

4.  The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices.

Authors:  Inge M Westra; Dorenda Oosterhuis; Geny M M Groothuis; Peter Olinga
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

5.  Stevia Prevents Acute and Chronic Liver Injury Induced by Carbon Tetrachloride by Blocking Oxidative Stress through Nrf2 Upregulation.

Authors:  Erika Ramos-Tovar; Erika Hernández-Aquino; Sael Casas-Grajales; Laura D Buendia-Montaño; Silvia Galindo-Gómez; Javier Camacho; Víctor Tsutsumi; Pablo Muriel
Journal:  Oxid Med Cell Longev       Date:  2018-04-19       Impact factor: 6.543

Review 6.  Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver.

Authors:  Luis E Soria-Jasso; Raquel Cariño-Cortés; Víctor Manuel Muñoz-Pérez; Elizabeth Pérez-Hernández; Nury Pérez-Hernández; Eduardo Fernández-Martínez
Journal:  Int J Mol Sci       Date:  2019-09-22       Impact factor: 5.923

7.  Hepatoprotective Effect of Metadoxine on Acetaminophen-induced Liver Toxicity in Mice.

Authors:  Parvin Mazraati; Mohsen Minaiyan
Journal:  Adv Biomed Res       Date:  2018-04-24

Review 8.  Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

Authors:  James J Connolly; Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2018-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.